Predictors of Thrombotic Events and Mortality in Patients Treated With Andexanet: A Pooled Analysis
BACKGROUND: Andexanet reduces hematoma expansion compared with usual care for acute FXa (factor Xa) inhibitor-associated intracerebral hemorrhage but is associated with a risk of thrombotic events (TE). We pooled data from andexanet-treated trial participants to determine baseline predictors of TE. METHODS: Secondary analyses of andexanet-treated participants in ANNEXA-I (Andexanet Alfa, a Novel Antidote to the Anticoagulant Effects of Factor Xa Inhibitors in ICH) and ANNEXA-4 (Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of Factor Xa Inhibitors), which included adults with acute life-threatening hemorrhage on FXa inhibitors. Stratified Cox proportional hazards models were used to examine associations between baseline variables and arterial or all TE and mortality. A stratified Cox regression model with arterial events as time-dependent covariates was used to examine associations of arterial events with mortality, adjusted for clinical covariates. RESULTS: Of 741 participants (mean age, 78.5 years; 54.5% male), 593 (80.0%) had intracranial hemorrhage and 109 (14.7%) had gastrointestinal hemorrhage. Seventy-seven (10.4%) participants had ≥1 TE, and 147 (19.8%) died. Arterial and venous thromboembolism events occurred a median of 3.5 days (interquartile range, 2.0-12.0) and 14.0 days (interquartile range, 10.0-20.0), respectively, after randomization. No baseline factors were associated with all TE. Arterial TE were associated with prior myocardial infarction (hazard ratio [HR], 2.64 [95% CI, 1.33-5.26]), high-dose eligibility (HR, 2.44 [95% CI, 1.33-4.48]), female sex (HR, 1.78 [95% CI, 1.00-3.16]), and age (HR per year, 1.04 [95% CI, 1.00-1.08]). Mortality was associated with arterial TE (HR, 2.68 [95% CI, 1.64-4.36]), prior congestive heart failure (HR, 2.53 [95% CI, 1.76-3.63]), intracerebral hemorrhage or intraventricular hemorrhage (HR, 1.90 [95% CI, 1.20-3.01]), and age (HR per year, 1.06 [95% CI, 1.03-1.08]). The initiation of anticoagulation after randomization was associated with a reduction in TE. CONCLUSIONS: In FXa inhibitor-associated hemorrhage treated with andexanet, baseline factors are associated with arterial TE and can be used to inform treatment decisions. Initiation of anticoagulation reduces the occurrence of TE. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02313909. URL: https://www.clinicaltrials.gov; Unique identifier: NCT02329327.
Authors
- Saskia Middeldorp (ORCID: https://orcid.org/0000-0002-1006-6420)
- Alexander Thomas Cohen (ORCID: https://orcid.org/0000-0002-9398-4621)
- Jan Beyer‐Westendorf (ORCID: https://orcid.org/0000-0002-6983-9993)
- Jonathan M. Coutinho (ORCID: https://orcid.org/0000-0002-8284-982X)
- Charles Michael Gibson (ORCID: https://orcid.org/0000-0002-4857-9125)
- Sven Poli (ORCID: https://orcid.org/0000-0002-0286-8781)
- Cecilia Falkenberg
- Johannes Sebastian Mutzenbach (ORCID: https://orcid.org/0000-0003-2802-4808)
- Else Charlotte Sandset (ORCID: https://orcid.org/0000-0003-4312-4778)
- Cameron D. Joyner
- Georgios K. Tsivgoulis (ORCID: https://orcid.org/0000-0002-0640-3797)
- Andrew M. Demchuk (ORCID: https://orcid.org/0000-0002-4930-7789)
- Robin Lemmens (ORCID: https://orcid.org/0000-0002-4948-5956)
- Pierre Amarenco (ORCID: https://orcid.org/0000-0002-3842-1236)
- David Tanné (ORCID: https://orcid.org/0000-0002-6699-2220)
- Truman John Milling (ORCID: https://orcid.org/0000-0002-5588-0426)
- Hanne Christensen (ORCID: https://orcid.org/0000-0002-7472-3194)
- Rohit Narayan
- Roland C. Veltkamp (ORCID: https://orcid.org/0000-0002-0583-1300)
- Ashkan Shoamanesh (ORCID: https://orcid.org/0000-0002-2802-1626)
- Raisa Kurlyandskaya (ORCID: https://orcid.org/0000-0002-2677-6056)
- Mukul Sharma (ORCID: https://orcid.org/0000-0002-6119-342X)
- Peter B. Verhamme (ORCID: https://orcid.org/0000-0001-8698-2858)
- Robert Mikulík (ORCID: https://orcid.org/0000-0002-7458-5166)
- Bernhard Ganser
- Danilo Toni (ORCID: https://orcid.org/0000-0003-2735-8427)
- Anna Członkowska (ORCID: https://orcid.org/0000-0002-1956-1866)
- Dániel Bereczki (ORCID: https://orcid.org/0000-0002-8374-0500)
- Arne G. Lindgren (ORCID: https://orcid.org/0000-0003-1942-7330)
- David Julian Seiffge (ORCID: https://orcid.org/0000-0003-3890-3849)
- Per Ladenvall (ORCID: https://orcid.org/0000-0002-0300-8070)
- Mark Andrew Crowther (ORCID: https://orcid.org/0000-0003-4986-4873)
- Nele Bubel
- Deborah M. Siegal (ORCID: https://orcid.org/0000-0003-3806-3245)
- G E Raskob
- Alexandra Bernegger (ORCID: https://orcid.org/0000-0001-7915-2696)
- Risto O. Roine (ORCID: https://orcid.org/0000-0002-3824-3003)
- John W. Eikelboom (ORCID: https://orcid.org/0000-0003-4126-1285)
- Ursula Leitner
- Melanie Baumgartinger
- Robin Hart (ORCID: https://orcid.org/0000-0002-7652-1174)
- Robinson T.G.
- H.R. Büller
- Mikael Knutsson
- ALEKSANDRA L LINDGREN
- S. Connolly (ORCID: https://orcid.org/0000-0002-5542-2898)
- D. George Wyse
- Carlos Alberto Molina (ORCID: https://orcid.org/0000-0001-6058-6259)
- H. Kohlfurst
- T. Tatlisumak
- S. Pikija
- E. Lenzenweger
- V. Tedim-Cruz
- M. Schonfelder
- L. Ritscher
- I. Krehan
- J. Cairns
- A. Rohracher
- G. Tsvigoulis
- M. Gaugg
- I. Oberdorfer
- W. Lang
- M. Komposch
- J. Ferrari
- A. Lindner
- G. Pilz
- B. Ramprecht
- A. Schiefecker
- A. Schmidt
- B. Pfausler
- J. Mente
- R. Beer
- Lizhen Xu
- E. Sandset
- S. Kasner
- E. Hoefner
- K. Mahaffey
- M. Prins
- C. Hecker
- K. Sorre
- C. Stadler
- J.H. Alexander
- D. Seiffge
- R. Roine
- S. Krebs
- D. Garcia
- L. Kellermair
- C.B. Sorschag
- V. Rass
- R. Helbok
- A. Pramsohler
- A. Kuschnig
- J. Coutinho
- T. Cook
- H. Novak
- F. Gruber
- C. Roesler
- M. Konrad
- S. Eger
Institutions
- Semmelweis University (HU)
- University of Bern (CH)
- Oslo University Hospital (NO)
- St Thomas' Hospital (GB)
- Harvard University (US)
- Radboud University Nijmegen (NL)
- University of Ottawa (CA)
- University of Calgary (CA)
- Technion – Israel Institute of Technology (IL)
- King's College London (GB)
- Lund University (SE)
- Guy's and St Thomas' NHS Foundation Trust (GB)
- National and Kapodistrian University of Athens (GR)
- Stiftelsen Norsk Luftambulanse (NO)
- Universitair Ziekenhuis Leuven (BE)
- University Hospital of Bern (CH)
- Rambam Health Care Campus (IL)
- Bispebjerg Hospital (DK)
- Turku University Hospital (FI)
- Copenhagen University Hospital (DK)
- Population Health Research Institute (CA)
- Radboud University Medical Center (NL)
- NIHR Imperial Biomedical Research Centre (GB)
- Vall d'Hebron Hospital Universitari (ES)
- Skåne University Hospital (SE)
- University General Hospital Attikon (GR)
- Hertie Institute for Clinical Brain Research (DE)
- AstraZeneca (Sweden) (SE)
- Hôpital Bichat-Claude-Bernard (FR)
- Alfried Krupp Hospital (DE)
- Amsterdam University Medical Centers (NL)
- Institute of Psychiatry and Neurology (PL)
- University Hospital Carl Gustav Carus (DE)
- Hotchkiss Brain Institute (CA)
- University of Houston (US)
- Imperial College London (GB)
- Hamilton Health Sciences (CA)
- University of Tübingen (DE)
- Sapienza University of Rome (IT)
- University of Amsterdam (NL)
- McMaster University (CA)
- KU Leuven (BE)
Publication Details
- Journal
- Stroke
- Published
- 2026-11-13
- DOI
- https://doi.org/10.1161/strokeaha.125.053981
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00